Analysts rate Biohaven Pharmaceuticals Holding Co Ltd. (BHVN:NYE) with a Hold rating

Based on the Biohaven Pharmaceuticals Stock Forecast from 6 analysts, the average analyst rating is a Hold. Stock Target Advisor’s own stock analysis of BHVN stock forecast is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Biohaven Pharmaceuticals stock price was USD 8.30Biohaven Pharmaceuticals stock price has changed by -143.90% over the past week, -141.36% over the past month and -94.18% over the last year.

Biohaven Pharmaceutical Holding Co Ltd stock forecasts from 3 Crowd Analysts, has the average Crowd target for Biohaven Pharmaceutical Holding Co Ltd at USD 12.33 over the next 12 months. Biohaven Pharmaceutical Holding Co Ltd’s average Crowd Rating is a Buy .


About Biohaven Pharmaceuticals Holding Co Ltd. (BHVN:NYE):

Biohaven Pharmaceuticals Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases. Its portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have four migraine attacks per month. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.


What we like:

High market capitalization:

Biohaven Pharmaceuticals is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns:

Biohaven stock has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.

High Gross Profit to Asset Ratio:

Biohaven stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.


What we don’t like:

Overpriced compared to book value:

BHVN stock price is trading high compared to its peers median on a price to book value basis.

Negative cashflow:

Biohaven Pharmaceuticals had negative total cash flow in the most recent four quarters.

Negative free cash flow:

Biohaven stock had negative total free cash flow in the most recent four quarters.

Low Earnings Growth:

Biohaven stock has shown below median earnings growth in the previous 5 years compared to its sector.